Entyvio 300 mg Powder for Concentrate: Uses, Dosing, Safety
Quick summary Entyvio is the brand name for vedolizumab, a biologic medicine used for ulcerative colitis and Crohn’s disease. It is given under medical supervision and is designed to act in the gut to...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
Entyvio is the brand name for vedolizumab, a biologic medicine used for ulcerative colitis and Crohn’s disease. It is given under medical supervision and is designed to act in the gut to help reduce inflammation.
Medical disclaimer:
This article is for general information only and does not replace the official patient leaflet, prescribing information, or advice from a doctor or pharmacist. Do not use it to self-diagnose, self-treat, or change any prescribed medicine.
What is Entyvio?
Entyvio 300 mg powder for concentrate for solution is a biologic medicine used in the treatment of inflammatory bowel disease. The active ingredient is vedolizumab.
It is used for adults with moderate to severe ulcerative colitis and moderate to severe Crohn’s disease. The original content also notes that it is available in intravenous and subcutaneous forms.
How Entyvio works
Entyvio works by blocking the interaction between lymphocytes and the gut. More specifically, it inhibits the α4β7 integrin, which helps prevent inflammatory cells from migrating into gut tissue.
This gut-focused action is intended to reduce inflammation in the digestive tract and may help improve symptoms such as diarrhea, abdominal pain, and fatigue.
When Entyvio is used
According to the original content, Entyvio is used for adults with:
- Moderate to severe ulcerative colitis
- Moderate to severe Crohn’s disease
- Inflammatory bowel disease that has not responded well to other therapies
Whether it is appropriate depends on the person’s medical history and treatment plan, so a healthcare professional should confirm the indication.
How Entyvio is given
The original content describes an initial intravenous infusion schedule of:
- Week 0
- Week 2
- Week 6
After that, some patients may transition to a subcutaneous form, depending on the treatment plan provided by their healthcare team.
Entyvio infusions are typically administered in a clinical setting and monitored by healthcare professionals. If a subcutaneous form is prescribed, patients should follow the training and instructions provided by their care team and the official leaflet.
Dosage and administration points to verify
The original content identifies 300 mg as the dose for the powder for concentrate formulation. Because dosing and administration can vary by product form and treatment phase, readers should verify the following with the official leaflet or their prescriber:
- Whether the medicine is being given by infusion or injection
- The exact schedule for the induction phase
- How maintenance treatment is planned
- How the medicine should be prepared and administered
| Topic | What the original content says | What to confirm |
|---|---|---|
| Active ingredient | Vedolizumab | Match the brand and formulation on the prescription |
| Strength | 300 mg | Check the exact product label and leaflet |
| Initial schedule | Weeks 0, 2, and 6 | Confirm the plan for the specific condition being treated |
| Administration | Infusion and/or subcutaneous form | Follow the route prescribed for the patient |
Possible side effects
As noted in the original content, Entyvio may cause side effects. Commonly mentioned effects include:
- Headache
- Fatigue
- Injection site reactions
The original content also mentions more serious concerns such as infusion reactions and the potential risk of progressive multifocal leukoencephalopathy (PML). Any new or worsening symptoms should be discussed with a healthcare professional promptly.
How the Entyvio Pen is used
The original content states that the subcutaneous form may be used at home after training from a healthcare provider. It also notes these general steps:
- Choose a clean, dry area on the thigh or abdomen.
- Rotate injection sites to help reduce skin irritation.
- Follow the instructions supplied with the medicine for use and disposal.
Patients should only use the device if they have been trained and if the prescribed product is intended for self-administration.
Support programs mentioned in the original content
The original content refers to EntyvioConnect as a support resource that may offer:
- Co-pay assistance
- Nurse support
- Resources related to treatment access
Availability and eligibility can vary, so readers should check the program details directly.
Frequently asked questions
▸ What is Entyvio used for?
The original content says Entyvio is used for adults with moderate to severe ulcerative colitis and Crohn’s disease, especially when other therapies have not worked well.
▸ What is the active ingredient in Entyvio?
The active ingredient is vedolizumab.
▸ How is Entyvio given?
The original content describes an initial intravenous infusion schedule at Weeks 0, 2, and 6, with some patients later moving to a subcutaneous form depending on the treatment plan.
▸ What side effects are mentioned?
Headache, fatigue, and injection site reactions are listed as common side effects in the original content. It also mentions infusion reactions and PML as serious concerns.
▸ Can Entyvio be used at home?
The original content says the subcutaneous form may be used at home after proper training from a healthcare provider. The infusion form is given in a clinical setting.
▸ Where can I confirm the correct dose and schedule?
The safest source is the official patient leaflet and the prescribing healthcare professional, because the exact schedule can depend on the product form and treatment plan.
Safety reminder: If you have questions about side effects, infusion reactions, injection technique, or whether this medicine is appropriate for you, speak with a doctor, pharmacist, or nurse using the official product information. Seek urgent medical help for severe or unexpected symptoms.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
- Entyvio official prescribing information
- European Medicines Agency: Entyvio
- U.S. FDA drug information search
- NHS medicines information
- Crohn’s & Colitis Foundation
To improve this article with specific references, add a custom field named _aio_sources in the post editor and write one source per line using: Source title|Source URL.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.